Efficacy and Safety of an Intelligent Insulin-Dosing Decision Support System for Glycemic Control in Patients With Type 2 Diabetes: A Randomized Controlled Study
NCT ID: NCT07291804
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2025-03-01
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Does the intelligent decision support system improve fasting glucose, postprandial glucose, and HbA1c?
* Does the system provide safe insulin titration without raising hypoglycemia risk and improve empowerment, self-management, and insulin-related attitudes?
Researchers will compare the intelligent insulin-dosing decision support system with usual care to see if the system leads to more effective and safer insulin titration.
Participants will:
* Upload blood glucose data using a smart glucometer connected to a mobile health platform
* Receive basal insulin therapy with ongoing dose adjustments
Intervention group: use the intelligent decision support system that provides algorithm-based insulin dose recommendations with remote monitoring and guidance Control group: receive standard diabetes education and routine outpatient insulin titration
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The system contains four major components. The first component is a comprehensive assessment module that collects demographic information, clinical characteristics, and a full panel of islet function indicators including fasting glucose, postprandial glucose, glycated hemoglobin, fasting insulin, and multiple C-peptide values. A validated hypoglycemia risk prediction model classifies each participant into low, intermediate, or high risk categories. Competency in insulin injection and dose verification is assessed using a standardized questionnaire.
The second component determines the initial basal insulin dose. This calculation follows guideline recommendations and incorporates the islet function results and hypoglycemia risk category to generate an individualized starting dose.
The third component evaluates insulin sensitivity and glucose response patterns. Continuous transmission of glucose values and insulin doses allows the system to estimate the participant's insulin sensitivity level and to update these estimates as additional data are obtained.
The fourth component produces dose adjustment recommendations. Titration is structured into three time-based phases with clearly defined monitoring frequencies and clinical review points. During the initial titration phase from day three to day fourteen, fasting glucose is measured daily and the system generates dose recommendations every three days using the mean of the most recent fasting glucose values. Nurses review glucose patterns and safety concerns on day four and at the end of the first week, while physicians perform dose verification on day four. During the stable titration phase from week three to week twelve, fasting glucose is measured every three days and the system generates weekly dose recommendations based on the most recent value. Nurses conduct follow up assessments and provide stepwise guidance at week one, week two, week four, week eight, and week twelve. Physicians review system-generated recommendations at the same time points. During the long term maintenance phase from week thirteen to week twenty four, fasting glucose is measured weekly and the system continues to produce weekly dose recommendations. Participants who demonstrate sufficient accuracy in dose verification by week twelve may be authorized to review system-generated dose units independently from week thirteen onward under remote supervision. Physicians complete a final evaluation at week twenty four.
Safety supervision is integrated throughout the entire study. The system continuously evaluates glucose fluctuations and recalculates hypoglycemia risk at each dose adjustment. When a fasting glucose value falls below the predefined safety threshold or when a proposed adjustment exceeds the predetermined limit, a safety alert is automatically triggered. Nurses are required to conduct follow up within twenty four hours and document the event. Both self-reported and device-captured hypoglycemia events are recorded and reviewed across the study period.
The mobile platform provides automated reminders for glucose monitoring, displays dose recommendations, and delivers educational content related to insulin use. Patients may submit questions and receive guidance through text or image messages. The clinician interface summarizes glucose trends, allows review of system-generated dose recommendations at scheduled verification points, and supports real time management of safety alerts.
The intervention incorporates a structured empowerment-based management process that aligns with the titration timeline. The five components include identifying patient challenges during insulin initiation, addressing concerns and emotional responses, establishing short term and long term treatment goals, developing individualized action plans, and evaluating outcomes at specific time points. Nurses and physicians conduct these steps at the designated visits that coincide with the initial, stable, and maintenance titration phases. The process is designed to gradually strengthen the participant's ability to verify dose adjustments, prevent hypoglycemia, and maintain long term adherence to basal insulin therapy.
Outcome measurements are collected at baseline and week twelve. These include glycemic indicators, hypoglycemia frequency, empowerment ability, self-management behaviors, and attitudes toward insulin therapy. Through this integrated system of algorithm-guided titration, continuous data monitoring, structured follow up, and staged empowerment education, this study aims to determine whether the intelligent dosing system can improve the precision and safety of basal insulin titration and enhance behavioral readiness for long term insulin self management.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Group
The control group received standard usual care, which included standardized diabetes education on the first day and routine follow-up where physicians adjusted insulin doses based on FPG levels during scheduled outpatient visits at Weeks 4, 8, 12, and 24.
No interventions assigned to this group
Intervention Group
The intervention group received usual care plus a structured program based on empowerment theory and implemented via an intelligent mHealth platform. This platform provided personalized dose recommendations and supported real-time data transmission ; physicians reviewed and confirmed dose adjustments at Day 4, Weeks 1, 2, 4, 8, 12, and 24 , and from Week 13 onward, patients were gradually authorized to self-adjust insulin doses under remote supervision.
Intelligent Insulin-Dosing Decision Support System
This intelligent insulin dosing system for type 2 diabetes operates on an IoT platform. Its core function begins with a comprehensive assessment that integrates patient data and islet function indicators to stratify hypoglycemia risk, followed by generating an individualized initial insulin dose based on guidelines and the risk category. The system then continuously estimates the patient's dynamic insulin sensitivity using real-time streams of glucose and insulin data. Dose titration is executed in three structured phases: an initial phase (Day 3-14) with adjustments every 3 days based on daily glucose, a stable phase (Week 3-12) with weekly adjustments using tri-weekly data, and a long-term maintenance phase (Week 13-24) with weekly recommendations, where eligible patients can begin remote-supervised self-management.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intelligent Insulin-Dosing Decision Support System
This intelligent insulin dosing system for type 2 diabetes operates on an IoT platform. Its core function begins with a comprehensive assessment that integrates patient data and islet function indicators to stratify hypoglycemia risk, followed by generating an individualized initial insulin dose based on guidelines and the risk category. The system then continuously estimates the patient's dynamic insulin sensitivity using real-time streams of glucose and insulin data. Dose titration is executed in three structured phases: an initial phase (Day 3-14) with adjustments every 3 days based on daily glucose, a stable phase (Week 3-12) with weekly adjustments using tri-weekly data, and a long-term maintenance phase (Week 13-24) with weekly recommendations, where eligible patients can begin remote-supervised self-management.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. were prescribed basal insulin therapy for the first time;
3. were aged 18 years or older;
4. voluntarily participated in this study; and
5. had access to mobile devices and the internet.
Exclusion Criteria
2. were unable to participate in regular follow-ups;
3. had communication or cognitive barriers;
4. had diagnosed psychiatric disorders; or
5. discontinued basal insulin therapy for non-glycaemic reasons.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiling Hu
Chief Nurse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025A1515012706
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
YHJH202404
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
RG-2025-025-02
Identifier Type: -
Identifier Source: org_study_id